{"product_id":"nvst-bcg-matrix","title":"(NVST) Envista Holdings Corp BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Envista Holdings Corp BCG Matrix helps you see how the company’s products or business units may be positioned across Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio review. The content shown on this page is a real preview of the actual report, not just sample marketing text, so you can review the format and insights before buying. Purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpark clear aligners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpark clear aligners are Envista’s flagship in orthodontics, a fast-growing segment that keeps taking share from braces. In 2025, it still needs heavy doctor training, channel support, and promotion to hold ground against larger aligner rivals, so it fits the BCG Star profile: high growth, high investment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDEXIS digital imaging\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDEXIS digital imaging stays a Stars fit because clinics keep shifting from film and older sensors to digital scanners, and Envista’s 2-segment model gives it broad dental reach. DEXIS benefits from a large installed base and software upgrades that lift repeat sales. In Envista’s 2025 filings, digital workflows remained a key growth driver, supporting higher-margin expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDTX Studio treatment planning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDTX Studio fits the Stars quadrant because digital treatment planning links diagnosis, planning, and execution in one workflow for implants and orthodontics. In a dental implants market expected to top $8 billion by 2026, tools that improve case flow and reduce chair time have clear upside. For Envista Holdings Corp, this makes DTX Studio a high-growth, high-strategy asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eImplant Direct value implants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImplant Direct fits a cost-sensitive market where procedure volume stays high and dentists keep trading down from premium brands. This gives Envista exposure to the value segment, but share is still below leaders like Straumann and Nobel Biocare, so more spend on sales, training, and distribution is needed to scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDemand is supported by price pressure.\u003c\/li\u003e\n\u003cli\u003eValue share still trails premium leaders.\u003c\/li\u003e\n\u003cli\u003eGrowth needs more commercial investment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eConnected digital workflow tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eConnected digital workflow tools are a small but improving Star in Envista Holdings Corp’s BCG mix. In 2025, dental spend keeps moving toward imaging, planning, and aligner-linked software, which helps Envista drive repeat use instead of one-time device sales. If adoption keeps rising, these workflows can turn into a more recurring, higher-margin cash stream.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLocks in recurring clinician use\u003c\/li\u003e\n\u003cli\u003eSupports imaging-to-aligner workflow\u003c\/li\u003e\n\u003cli\u003eCan lift future margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnvista’s Digital Stars: Spark, DEXIS, and the Workflow Shift\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars in Envista Holdings Corp center on Spark aligners, DEXIS imaging, DTX Studio, and connected digital workflows. These lines ride the shift to digital dentistry and orthodontics, where Envista’s 2025 filings show growth needs continued spend on training, software, and channel support to protect share and lift margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpark\u003c\/td\u003e\n\u003ctd\u003eHigh-growth aligners\u003c\/td\u003e\n\u003ctd\u003eFlagship\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDEXIS\u003c\/td\u003e\n\u003ctd\u003eDigital workflow shift\u003c\/td\u003e\n\u003ctd\u003eInstalled base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eEnvista Holdings Corp BCG Matrix maps dental brands by growth and share, guiding invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eEnvista Holdings Corp BCG Matrix made simple for fast portfolio clarity\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise source trail for Envista Holdings Corp, boosting credibility and making key assumptions easy to verify for faster decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNobel Biocare premium implants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNobel Biocare is Envista Holdings Corp’s classic cash cow: a premium implant franchise with strong brand recall and repeat clinical use. Implant dentistry is more mature than aligners or software, so growth is steadier, but demand is resilient and margins tend to stay attractive. In Envista Holdings Corp’s 2025 base, this kind of high-share, recurring implant business helps fund faster-growing bets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKerr restorative materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKerr restorative materials sit in a mature, high-volume dental market, where cements, adhesives, and restorative materials are bought again and again through dental channels. Envista Holdings Corp reported about $2.6 billion in 2025 revenue, and this line helps support stable cash flow with low heavy growth spend. That makes Kerr a classic cash cow in the BCG matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKerr endodontics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKerr endodontics fits Cash Cows because its consumables and kits are repeat-buy items, not one-time capital sales. Demand is tied to routine root canal work, so it stays steadier than $20,000+ dental equipment cycles. That supports dependable cash flow and strong margins for Envista Holdings Corp.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOrmco fixed appliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOrmco fixed appliances fit the Cash Cows bucket because traditional brackets and wire systems are a mature orthodontic line with slower growth than clear aligners, but they still sit on a deep installed base of clinics and long-running customer ties. That makes them a steady source of revenue and cash for Envista Holdings Corp, even if the segment is not the main growth engine.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMature market, low growth\u003c\/li\u003e\n\u003cli\u003eInstalled customer base supports repeat sales\u003c\/li\u003e\n\u003cli\u003eStable cash flow helps fund growth areas\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFor Envista Holdings Corp, this franchise is less about fast expansion and more about dependable monetization from an established product set. In BCG terms, that steady demand and customer retention make Ormco fixed appliances a classic Cash Cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOrascoptic loupes and lighting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOrascoptic loupes and lighting fit the cash-cow profile: the tools are standard in many dental workflows, the market is mature, and repeat replacement demand stays steady. Envista’s 2025 filings show the Dental segment still delivered scale, with roughly $2.6 billion in full-year net sales across the company, supporting a high-cash, low-growth category. Brand trust matters here, so loyal users tend to repurchase rather than switch.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable, mature dental category\u003c\/li\u003e\n\u003cli\u003eStrong brand loyalty\u003c\/li\u003e\n\u003cli\u003eRepeat replacement demand\u003c\/li\u003e\n\u003cli\u003eReliable cash generation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnvista’s Cash Cows Keep Sales and Cash Flow Steady\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnvista Holdings Corp’s Cash Cows are its mature dental lines: Nobel Biocare, Kerr, Ormco, and Orascoptic. These businesses sit in slow-growth markets, but they keep generating repeat sales from installed users and routine care. In 2025, Envista Holdings Corp posted about $2.6 billion in net sales, and these franchises helped anchor cash flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLine\u003c\/th\u003e\n\u003cth\u003eWhy\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNobel Biocare\u003c\/td\u003e\n\u003ctd\u003ePremium implants, repeat use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKerr\u003c\/td\u003e\n\u003ctd\u003eConsumables, steady replenishment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrmco\u003c\/td\u003e\n\u003ctd\u003eMature braces, loyal clinics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrascoptic\u003c\/td\u003e\n\u003ctd\u003eReplacement demand, brand trust\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eEnvista Holdings Corp Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Envista Holdings Corp BCG Matrix preview you see here is the exact document you’ll receive after purchase. It’s the full, professionally formatted file—no placeholders, no demo content. Download it instantly and use it for analysis, presentations, or strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy analog imaging\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy analog imaging at Envista Holdings Corp is a clear Dog: older film-based and basic analog workflows keep losing share to digital systems, so demand is weak and pricing power stays low. In Envista Holdings Corp’s 2024 mix, digital products were the growth engine, while legacy formats faced steady replacement pressure. That makes this line low-growth and hard to defend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandalone chair units\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStandalone chair units are a clear Dogs business for Envista Holdings Corp because basic chair hardware is heavily commoditized, so buyers often pick the lowest price, not the brand. In a slow-growth dental equipment slice, that weakens margins and cash returns. Without clear product differentiation, this segment usually earns below-mean returns and gets squeezed by cheaper rivals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommodity burs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCommodity burs sit in a crowded, price-driven market, so even if they are essential, they offer little room for differentiation. With modest growth and low switching costs, they fit a weak Dog position in Envista Holdings Corp's BCG matrix. That makes long-term value creation hard unless Envista can cut costs or bundle them with higher-margin products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eManual impression materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eManual impression materials are a Dog for Envista Holdings Corp: traditional workflows are losing share to digital scanning, and the category is mature with weak growth. That makes it a cash trap risk, because demand can fade while fixed costs stay in place.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDigital scanning keeps taking share\u003c\/li\u003e\n\u003cli\u003eMature category, structural pressure\u003c\/li\u003e\n\u003cli\u003eLow growth, weak reinvestment case\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor Envista Holdings Corp, this is a hold-and-harvest business, not a growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLow-end accessory SKUs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLow-end accessory SKUs in Envista Holdings Corp’s Dental segment fit the Dogs box: they add little strategic lift and can drag on gross margin through stocking, handling, and sales effort. Envista reported 2024 net sales of about $2.5 billion, but small accessory lines usually sit far below core implant and equipment growth, so trimming them helps protect cash and working capital.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow margin, weak growth\u003c\/li\u003e\n\u003cli\u003eInventory and selling cost drag\u003c\/li\u003e\n\u003cli\u003eMinimize, don’t expand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnvista’s Dogs: Low-Growth Legacy Lines to Harvest, Not Grow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnvista Holdings Corp’s Dogs are legacy analog imaging, chair units, burs, impression materials, and low-end accessories: all sit in low-growth, price-led niches with weak switching costs. In 2024, Envista reported about $2.5 billion in net sales, but these lines add little scale or margin. The right move is to harvest cash, cut SKUs, and avoid new capex.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eLegacy lines\u003c\/td\u003e\n\u003ctd\u003eLow growth, commoditized, weak margins\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI imaging software\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAI imaging software is a Question Mark for Envista Holdings Corp: AI-enabled dental diagnostics are growing fast, but clinic adoption is still early. DEXIS gives Envista a real channel to scale these tools across thousands of dental offices, yet share is not proven. The upside is high, but 2025 traction still looks too small to call it a leader.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntraoral scanner expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntraoral scanner demand is still expanding at a double-digit pace in 2025, so this sits in Envista Holdings Corp’s question mark bucket: high growth, still limited share. Envista can build position by linking scanners with imaging and treatment planning, which can lift software attach rates and recurring use. If adoption keeps rising, this business can move from question mark toward star status.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e3D printing workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e3D printing workflows are moving into chairside and lab use, and Envista holds real growth exposure through dental restoration demand. The catch is scale: the category is still fragmented, with many hardware and software rivals. That means Envista may need heavy upfront spend before printing turns into a material profit driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEmerging-market Spark rollout\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSpark’s emerging-market rollout is a classic question mark: clear aligner demand is rising beyond North America and Western Europe, but Spark’s share still swings by country and by channel. That means Envista Holdings Corp must spend on local sales, orthodontist education, and distributor coverage before the payoff is clear. If adoption scales, Spark can move from niche to growth engine; if not, it stays a cash drag.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDemand is widening outside core markets\u003c\/li\u003e\n\u003cli\u003eShare varies by region and channel\u003c\/li\u003e\n\u003cli\u003eRollout needs upfront investment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCloud dental subscriptions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCloud dental subscriptions are a BCG Question Mark for Envista Holdings Corp: they can turn clinic software into recurring revenue, but adoption is still early. The opportunity matters because dental software spend is moving toward cloud tools, so even small penetration can scale fast if Envista funds product, sales, and onboarding now.\u003c\/p\u003e\n\u003cp\u003eTo be fair, this is still a build phase, not a harvest phase, so near-term margin pressure is the trade-off. The key test is whether Envista can convert first users into sticky, high-retention accounts before rivals lock in the installed base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring revenue can lift visibility.\u003c\/li\u003e\n\u003cli\u003ePenetration is still early.\u003c\/li\u003e\n\u003cli\u003eInvestment now can buy future share.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnvista’s Early Bets: High Upside, Still Proving Share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnvista Holdings Corp’s question marks are early-growth bets with limited share in 2025: AI imaging, intraoral scanners, 3D printing, Spark rollout, and cloud dental software. They can scale fast if adoption sticks, but each still needs spend on product, sales, and onboarding before cash flow is clear.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003cth\u003eBCG view\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI imaging\u003c\/td\u003e\n\u003ctd\u003eEarly adoption\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpark rollout\u003c\/td\u003e\n\u003ctd\u003eShare varies by region\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234759385353,"sku":"nvst-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/nvst-bcg-matrix.webp?v=1785726963","url":"https:\/\/dcfanalyst.com\/products\/nvst-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}